227 related articles for article (PubMed ID: 27617579)
1. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2.
Liu T; Xiong J; Yi S; Zhang H; Zhou S; Gu L; Zhou M
Oncogene; 2017 Mar; 36(12):1678-1686. PubMed ID: 27617579
[TBL] [Abstract][Full Text] [Related]
2. FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer.
Xing M; Wang J; Yang Q; Wang Y; Li J; Xiong J; Zhou S
Cancer Chemother Pharmacol; 2019 Oct; 84(4):861-872. PubMed ID: 31428819
[TBL] [Abstract][Full Text] [Related]
3. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer.
Singh AK; Chauhan SS; Singh SK; Verma VV; Singh A; Arya RK; Maheshwari S; Akhtar MS; Sarkar J; Rangnekar VM; Chauhan PMS; Datta D
Carcinogenesis; 2016 Nov; 37(11):1027-1040. PubMed ID: 27543608
[TBL] [Abstract][Full Text] [Related]
6. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways.
Zheng T; Wang J; Song X; Meng X; Pan S; Jiang H; Liu L
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1597-604. PubMed ID: 20174822
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
9. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
[TBL] [Abstract][Full Text] [Related]
11. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
12. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
Vaseva AV; Marchenko ND; Moll UM
Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846
[TBL] [Abstract][Full Text] [Related]
13. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
14. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
15. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
Carter BZ; Mak DH; Schober WD; Koller E; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2010 Jan; 115(2):306-14. PubMed ID: 19897582
[TBL] [Abstract][Full Text] [Related]
18. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells.
Ghassemifar S; Mendrysa SM
Neurosci Lett; 2012 Mar; 513(1):106-10. PubMed ID: 22343310
[TBL] [Abstract][Full Text] [Related]
19. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
